Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 86 articles:
HTML format



Single Articles


    July 2022
  1. DU J, Wei R, Jiang S, Jiang H, et al
    CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.
    Am J Hematol. 2022;97:933-941.
    PubMed     Abstract available


  2. ABUSHUKAIR H, Syaj S, Ababneh O, Qarqash A, et al
    First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstrom's Macroglobulinemia: A systematic review and meta-analysis.
    Am J Hematol. 2022;97:942-950.
    PubMed     Abstract available


    June 2022
  3. LIM JQ, Huang D, Chan JY, Laurensia Y, et al
    A genomic-augmented multivariate prognostic model for the survival of Natural-killer/T-cell lymphoma patients from an international cohort.
    Am J Hematol. 2022 Jun 20. doi: 10.1002/ajh.26636.
    PubMed     Abstract available


  4. SEEGOBIN K, Li Z, Alhaj Moustafa M, Majeed U, et al
    Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003-2018).
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26635.
    PubMed     Abstract available


    May 2022
  5. SAUL EE, Alderuccio JP, Reis IM, Zhao W, et al
    Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma.
    Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26591.
    PubMed     Abstract available


  6. EVANS MG, Crymes A, Crombie JL, Basu SS, et al
    Monotypic plasmacytoid cells mimicking lymph node malignancy in the setting of COVID-19 recovery.
    Am J Hematol. 2022;97:666-667.
    PubMed    


    April 2022
  7. MALPICA L, Marques-Piubelli ML, Beltran BE, Chavez JC, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26579.
    PubMed     Abstract available


  8. HOPKINS D, Smyth D, Leach M, Bain BJ, et al
    Breast implant-associated anaplastic large cell lymphoma.
    Am J Hematol. 2022 Apr 20. doi: 10.1002/ajh.26574.
    PubMed    


  9. BANSAL R, Novo M, Al Saleh AS, Guerrico AG, et al
    Peak Absolute Lymphocyte Count After CAR-T Infusion Predicts Clinical Response in Aggressive Lymphoma.
    Am J Hematol. 2022 Apr 6. doi: 10.1002/ajh.26561.
    PubMed    


    March 2022
  10. COOK L, Al-Yousuf H, Mohamedbhai S, Bain BJ, et al
    Hyposplenism in adult T-cell leukemia/lymphoma.
    Am J Hematol. 2022 Mar 26. doi: 10.1002/ajh.26547.
    PubMed    


  11. OVLISEN AK, Jakobsen LH, Kragholm KH, Nielsen RE, et al
    Mental Health Among Patients with non-Hodgkin Lymphoma: a Danish Nationwide Study of Psychotropic Drug Use in 8,750Patients and 43,750 Matched Comparators.
    Am J Hematol. 2022 Mar 17. doi: 10.1002/ajh.26538.
    PubMed     Abstract available


  12. EVENS AM, Brandt JS, Peer CJ, Yin T, et al
    Checkpoint Inhibitor Immunotherapy during Pregnancy for Relapsed/Refractory Hodgkin Lymphoma.
    Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26527.
    PubMed    


  13. JAIN P, Wang M
    Mantle cell lymphoma in 2022 - A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
    Am J Hematol. 2022 Mar 10. doi: 10.1002/ajh.26523.
    PubMed     Abstract available


  14. TA R, Hasserjian RP, Nardi V
    An Unusual Lymphoma Involving the GI Tract and Bone Marrow.
    Am J Hematol. 2022 Mar 7. doi: 10.1002/ajh.26513.
    PubMed    


    February 2022
  15. POMMERT L, Schafer ES, Malvar J, Gossai N, et al
    Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26510.
    PubMed     Abstract available


  16. YHIM HY, Eshet Y, Metser U, Lajkosz K, et al
    Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pre-transplant Deauville score and residual metabolic tumor volume.
    Am J Hematol. 2022 Feb 16. doi: 10.1002/ajh.26500.
    PubMed     Abstract available


  17. WANG Y, Zhang M, Song W, Cai Q, et al
    Chidamide plus Prednisone, Etoposide, and Thalidomide for Untreated Angioimmunoblastic T-cell Lymphoma in a Chinese Population: A Multicenter Phase II Trial.
    Am J Hematol. 2022 Feb 15. doi: 10.1002/ajh.26499.
    PubMed     Abstract available


  18. UJJANI C, Greninger AL, Shadman M, Hill JA, et al
    Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Am J Hematol. 2022;97:E67-E69.
    PubMed    


    January 2022
  19. DORFMAN DM, Pinkus GS
    A case of peripheral T-cell lymphoma, NOS mimicking acute monocytic leukemia.
    Am J Hematol. 2022 Jan 22. doi: 10.1002/ajh.26476.
    PubMed    


  20. PHILLIPS T, Brunvand M, Chen AI, Essell J, et al
    Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
    Am J Hematol. 2022;97:E24-E27.
    PubMed    


    December 2021
  21. MOSHREF RAZAVI H, Henrie R, Hrynchak M, Minor A, et al
    Aggressive B cell lymphoma with t(3;8)(q27;q24). in an elderly patient.
    Am J Hematol. 2021 Dec 6. doi: 10.1002/ajh.26430.
    PubMed    


    October 2021
  22. KOZAK M, Eno C, Vail E, Kitahara S, et al
    The elusive but classic presentation of small cell variant of ALK+ anaplastic large cell lymphoma (ALCL).
    Am J Hematol. 2021 Oct 29. doi: 10.1002/ajh.26394.
    PubMed    


  23. ZHANG T, Lu Y, Liu X, Zhao M, et al
    Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B cell lymphoma.
    Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26392.
    PubMed    


  24. HO M, Zanwar S, Duggan P, Carr R, et al
    Hiding in (Not So) Plain Sight: Spontaneous Tumor Lysis Syndrome due to Intravascular Large B Cell Lymphoma.
    Am J Hematol. 2021 Oct 22. doi: 10.1002/ajh.26383.
    PubMed     Abstract available


  25. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
    BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Am J Hematol. 2021;96:1195-1203.
    PubMed     Abstract available


  26. BARRETO JN, Bansal R, Hathcock MA, Doleski CJ, et al
    The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy.
    Am J Hematol. 2021;96:E399-E402.
    PubMed    


  27. TINTLE S, Fuda F, Chen W
    Restricted TRBC1 expression: A clonality marker for circulating Sezary cells.
    Am J Hematol. 2021;96:1338-1339.
    PubMed    


  28. WESTIN JR, Kersten MJ, Salles G, Abramson JS, et al
    Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Am J Hematol. 2021;96:1295-1312.
    PubMed     Abstract available


  29. HRISTOV AC, Tejasvi T, A Wilcox R
    Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2021;96:1313-1328.
    PubMed     Abstract available



  30. Abstracts from the 2021 Lymphoma and Myeloma Congress October 19-23, 2021.
    Am J Hematol. 2021;96 Suppl 1:S3-S33.
    PubMed    


    September 2021
  31. S MEHTA R, Torres Cabala CA, DiNardo CD, Daver N, et al
    Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis.
    Am J Hematol. 2021;96:E350-E353.
    PubMed    


    August 2021
  32. SIOW W, Matthey F, Bain BJ
    Eosinophil morphology in the reactive eosinophilia of Hodgkin lymphoma.
    Am J Hematol. 2021 Aug 30. doi: 10.1002/ajh.26337.
    PubMed    


  33. ZHANG Y, Ma S, Cai J, Yang Y, et al
    Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: a multicenter study.
    Am J Hematol. 2021 Aug 27. doi: 10.1002/ajh.26335.
    PubMed     Abstract available


  34. WUDHIKARN K, Bansal R, Khurana A, Hathcock MA, et al
    Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.
    Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26330.
    PubMed    


  35. JURGENS EM, Ketas TJ, Zhao Z, Satlin MJ, et al
    Serologic response to mRNA COVID-19 vaccination in lymphoma patients.
    Am J Hematol. 2021 Aug 14. doi: 10.1002/ajh.26322.
    PubMed    


  36. ZAIN JM, Hanona P
    Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:1027-1046.
    PubMed     Abstract available


    July 2021
  37. KARMALI R, Switchenko JM, Goyal S, Shanmugasundaram K, et al
    Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era.
    Am J Hematol. 2021 Jul 29. doi: 10.1002/ajh.26306.
    PubMed     Abstract available


  38. KHURANA A, Hathcock M, Habermann TM, Al Saleh A, et al
    Lines of Therapy before Autologous Stem Cell Transplant and CAR-T Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma.
    Am J Hematol. 2021 Jul 14. doi: 10.1002/ajh.26293.
    PubMed    


  39. CASTILLO JJ, Lamacchia J, Silver J, Flynn CA, et al
    Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma.
    Am J Hematol. 2021 Jul 14. doi: 10.1002/ajh.26291.
    PubMed    


  40. MEHTA-SHAH N, Lunning MA, Moskowitz AJ, Boruchov AM, et al
    Romidepsin and lenalidomide based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts.
    Am J Hematol. 2021 Jul 12. doi: 10.1002/ajh.26288.
    PubMed     Abstract available


  41. VAUGHN JL, Spies D, Xavier AC, Epperla N, et al
    Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States.
    Am J Hematol. 2021;96:816-822.
    PubMed     Abstract available


    June 2021
  42. SARKOZY C, Michot JM, Quivoron C, Camara-Clayette V, et al
    Innovative therapies based on molecular orientation in patients with Relapse and Refractory diffuse large B cell lymphoma, results of LNH-EP1 study.
    Am J Hematol. 2021 Jun 24. doi: 10.1002/ajh.26280.
    PubMed    


  43. DEFRANCESCO I, Visentini M, Zibellini S, Minafo YA, et al
    Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.
    Am J Hematol. 2021;96:E210-E214.
    PubMed    


    May 2021
  44. MARTINEZ-CALLE N, Wilson MR, Eyre TA, Cwynarski K, et al
    Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in Diffuse Large B-cell Lymphoma; caution required.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26257.
    PubMed    


  45. PUCKRIN R, Stewart DA
    Prophylactic high-dose methotrexate in diffuse large B cell lymphoma, authors' response.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26256.
    PubMed    


  46. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
    PubMed    


  47. KHURANA A, Dalland J, Young JR, Inwards DJ, et al
    Brexucabtagene Autoleucel Therapy Induces Complete Remission in a Primary Refractory Blastoid Mantle Cell Lymphoma with Neurolymphomatosis.
    Am J Hematol. 2021 May 13. doi: 10.1002/ajh.26233.
    PubMed    


  48. BODDICKER NJ, Larson MC, Castellino A, Herrmann J, et al
    Anthracycline Treatment, Cardiovascular Risk Factors and the Cumulative Incidence of Cardiovascular Disease in a Cohort of Newly Diagnosed Lymphoma Patients from the Modern Treatment Era.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26230.
    PubMed     Abstract available


    April 2021
  49. DULERY R, Lamure S, Delord M, Di Blasi R, et al
    Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.
    Am J Hematol. 2021 Apr 28. doi: 10.1002/ajh.26209.
    PubMed     Abstract available


  50. WALTER LP, Couronne L, Jais JP, Nguyen PD, et al
    Outcome after Haematopoietic Stem Cell Transplantation in Patients with Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: a French Study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26200.
    PubMed     Abstract available


  51. LAM M, Touitou V, Choquet S, Cassoux N, et al
    Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26199.
    PubMed     Abstract available


  52. PUCKRIN R, El Darsa H, Ghosh S, Peters A, et al
    Ineffectiveness of High-Dose Methotrexate for Prevention of CNS Relapse in Diffuse Large B Cell Lymphoma.
    Am J Hematol. 2021 Apr 3. doi: 10.1002/ajh.26181.
    PubMed     Abstract available


  53. NAGLE SJ, Murphree C, Raess PW, Schachter L, et al
    Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
    Am J Hematol. 2021;96:455-461.
    PubMed     Abstract available


    March 2021
  54. ALDERUCCIO JP, Saul EE, Iyer SG, Reis IM, et al
    R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - long term follow up results.
    Am J Hematol. 2021 Mar 18. doi: 10.1002/ajh.26163.
    PubMed     Abstract available


  55. QUINN D, Farrell K, Leach M, Bain BJ, et al
    An aggressive NK-cell lymphoma with hemophagocytosis.
    Am J Hematol. 2021 Mar 11. doi: 10.1002/ajh.26154.
    PubMed    


  56. MAURER MJ, Jakobsen LH, Mwangi R, Schmitz N, et al
    R/R International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
    Am J Hematol. 2021 Mar 4. doi: 10.1002/ajh.26149.
    PubMed     Abstract available


  57. SUSANIBAR-ADANIYA S, Barta SK
    2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
    Am J Hematol. 2021 Mar 4. doi: 10.1002/ajh.26151.
    PubMed     Abstract available


  58. HIGGINS A, Kim H, Harper L, Habermann TM, et al
    Testicular FDG-PET/CT uptake threshold in aggressive lymphomas.
    Am J Hematol. 2021;96:E81-E83.
    PubMed    


  59. LAUDE MC, Lebras L, Sesques P, Ghesquieres H, et al
    First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.
    Am J Hematol. 2021;96:302-311.
    PubMed     Abstract available


    February 2021
  60. MORITA K, Jain N, Kantarjian H, Takahashi K, et al
    Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine.
    Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26144.
    PubMed     Abstract available


    January 2021
  61. JAIN P, Kanagal-Shamanna R, Zhang S, Ok CY, et al
    Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
    Am J Hematol. 2021 Jan 25. doi: 10.1002/ajh.26109.
    PubMed    


  62. VAUGHN JL, Pinheiro LC, Olszewski A, Epperla N, et al
    Survival of Patients with Marginal Zone Lymphoma in the United States: A Population-Based Cohort Study (2000 to 2017).
    Am J Hematol. 2021 Jan 21. doi: 10.1002/ajh.26103.
    PubMed    


    October 2020
  63. TOBIN JW, Gandhi MK
    Risk-Adapted Therapy in Follicular Lymphoma: Is it time to FLEX?
    Am J Hematol. 2020 Oct 8. doi: 10.1002/ajh.26016.
    PubMed    



  64. Abstracts from the 2020 Lymphoma, Leukemia and Myeloma Congress October 21-24, 2020.
    Am J Hematol. 2020;95 Suppl 1:S3-S38.
    PubMed    


    September 2020
  65. NGUYEN MN, Nayernama A, Jones SC, Kanapuru B, et al
    Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
    Am J Hematol. 2020;95:E218-E222.
    PubMed    


    August 2020
  66. LUO DX, Li W, Ye MT, Yang Y, et al
    "Double Hit" Anaplastic Large Cell Lymphoma with Concurrent ALK and MYC Rearrangements.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25980.
    PubMed    


  67. BEIN J, Thurner L, Hansmann ML, Hartmann S, et al
    Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse.
    Am J Hematol. 2020 Aug 20. doi: 10.1002/ajh.25972.
    PubMed     Abstract available


  68. MIR F, Mattiello F, Grigg A, Herold M, et al
    Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
    Am J Hematol. 2020 Aug 20. doi: 10.1002/ajh.25973.
    PubMed     Abstract available


  69. BOSSI E, Aroldi A, Brioschi FA, Steidl C, et al
    Phase II study of crizotinib in patients with Anaplastic Lymphoma Kinase (ALK) positive Anaplastic Large Cell Lymphoma relapsed/refractory to chemotherapy.
    Am J Hematol. 2020 Aug 18. doi: 10.1002/ajh.25967.
    PubMed    


  70. CANDONI A, Lazzarotto D, Ferrara F, Curti A, et al
    Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma. the campus-all study.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25957.
    PubMed     Abstract available


  71. FLORINDEZ JA, Alderuccio JP, Reis IM, Lossos IS, et al
    Survival Analysis in Treated Plasmablastic Lymphoma Patients: a Population-based Study.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25955.
    PubMed     Abstract available


  72. SESQUES P, Ferrant E, Safar V, Wallet F, et al
    Use of Commercial anti-CD19 CAR T Cell Therapy for Patients with Relapsed/Refractory Aggressive B Cell Lymphoma in a European center.
    Am J Hematol. 2020 Aug 3. doi: 10.1002/ajh.25951.
    PubMed     Abstract available


    July 2020
  73. AMINI RM, Ljungstrom V, Abdulla M, Cavelier L, et al
    Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome.
    Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25927.
    PubMed    


    June 2020
  74. SAMRA B, Alotaibi AS, Short NJ, Khoury JD, et al
    Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Am J Hematol. 2020 Jun 5. doi: 10.1002/ajh.25896.
    PubMed    


    May 2020
  75. QI SN, Yang Y, Zhang YJ, Huang HQ, et al
    Risk-based, Response-adapted Therapy for Early-stage Extranodal Nasal-type NK/T-cell Lymphoma in the Modern Chemotherapy Era: A China Lymphoma Collaborative Group (CLCG) Study.
    Am J Hematol. 2020 May 25. doi: 10.1002/ajh.25878.
    PubMed     Abstract available


  76. MONDELLO P, Musolino C, Dogliotti I, Bohn JP, et al
    ABVD vs BEACOPP escalated in Advanced-Stage Hodgkin's Lymphoma: results from a multicenter European study.
    Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25871.
    PubMed     Abstract available


  77. ANSELL SM
    Hodgkin Lymphoma: 2020 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2020 May 8. doi: 10.1002/ajh.25856.
    PubMed     Abstract available


  78. JAIN P, Tang G, Li S, Wang M, et al
    "Triple Hit" SOX-11(-) , CD10(+) , TP53 mutated high-grade pleomorphic mantle cell lymphoma.
    Am J Hematol. 2020 May 1. doi: 10.1002/ajh.25848.
    PubMed    


    April 2020
  79. DHARMAVARAM G, Cao S, Sundaram S, Ayyapan S, et al
    Aggressive Lymphoma Subtype Is A Risk Factor for Venous Thrombosis. Development of Lymphoma - Specific Venous Thrombosis Prediction Models.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25837.
    PubMed     Abstract available


  80. CHOW VA, Rajendran JG, Fisher DR, Appelbaum FR, et al
    A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25818.
    PubMed     Abstract available


  81. KEMPS PG, Cleven AHG, van Wezel T, van Eijk R, et al
    B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25801.
    PubMed    


  82. ZHAO S, Kanagal-Shamanna R, Navsaria L, Chi Young OK, et al
    Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
    Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25796.
    PubMed     Abstract available


  83. WANG W, Zhang Y, Zhang L, Yang C, et al
    Intravenous methotrexate at a dose of 1 g/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study.
    Am J Hematol. 2020;95:E80-E83.
    PubMed    


    March 2020
  84. EL CHAER F, Siegel A, Holtzman NG, Bukhari A, et al
    Severe Dysautonomia as a Manifestation of Neurotoxicity after CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma.
    Am J Hematol. 2020 Mar 31. doi: 10.1002/ajh.25794.
    PubMed    


  85. ZANWAR S, Abeykoon JP, Durot E, King R, et al
    Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom Macroglobulinemia.
    Am J Hematol. 2020;95:274-281.
    PubMed     Abstract available


    February 2020
  86. FOSS FM, Horwitz SM, Civallero M, Bellei M, et al
    Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.
    Am J Hematol. 2020;95:151-155.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: